Oligonucleotide aptamers: New tools for targeted cancer therapy

Molecular Therapy Nucleic Acids

Volumn 3, Issue , 2014, Pages

  Sun, Hongguang ^a   Zhu, Xun ^b   Lu, Patrick Y ^c   Rosato, Roberto R ^a   Tan, Wen ^d   Zu, Youli ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b Basic Medical College   (China)

^c Sirnaomics Inc   (United States)

^d SOUTH CHINA UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

cell surface biomarker; nanomedicine; oligonucleotide aptamer; SELEX; targeted cancer therapy

Indexed keywords

APTAMER; COPOLYMER; LIPOSOME; NANOPARTICLE; PROTEIN ANTIBODY; BIOLOGICAL MARKER; METAL; NANOMATERIAL; OLIGONUCLEOTIDE;

ARTICLE; CANCER IMMUNOTHERAPY; CELL SURFACE; CLINICAL TRIAL (TOPIC); COMBINATORIAL CHEMISTRY; DATA BASE; DRUG CONJUGATION; GENE TARGETING; GENE THERAPY; HUMAN; MOLECULARLY TARGETED THERAPY; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; STAINING; TARGET CELL; APTAMER DRUG CONJUGATION; APTAMER MEDIATED BIOTHERAPY; APTAMER MEDIATED IMMUNOTHERAPY; APTAMER MEDIATED TARGETED GENE THERAPY; DRUG DELIVERY SYSTEM; DRUG DEVELOPMENT; DRUG EFFICACY; GENE SILENCING; IMMUNOTHERAPY; IN VITRO STUDY; PROSTATE CANCER; SELEX TECHNOLOGY; SURFACE PROPERTY; SUSTAINED DRUG RELEASE; TECHNOLOGY;

EID: 84907312881     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2014.32     Document Type: Review

References (143)

1. Ellington, AD and Szostak, JW (1990). In vitro selection of RNA molecules that bind specific ligands. Nature 346: 818-822
2. Tuerk, C and Gold, L (1990). Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249: 505-510
3. Nimjee, SM, Rusconi, CP and Sullenger, BA (2005). Aptamers: an emerging class of therapeutics. Annu Rev Med 56: 555-583 (Pubitemid 40299797)
4. Eyetech Study Group (2002). Preclinical and phase 1A clinical evaluation of an anti- VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 22: 143-152
5. Eyetech Study Group (2003). Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 110: 979-986
6. Parekh, P, Tang, Z, Turner, PC, Moyer, RW and Tan, W (2010). Aptamers recognizing glycosylated hemagglutinin expressed on the surface of vaccinia virus-infected cells. Anal Chem 82: 8642-8649
7. Sefah, K, Tang, ZW, Shangguan, DH, Chen, H, Lopez-Colon, D, Li, Y et al. (2009). Molecular recognition of acute myeloid leukemia using aptamers. Leukemia 23: 235-244
8. Bayrac, AT, Sefah, K, Parekh, P, Bayrac, C, Gulbakan, B, Oktem, HA et al. (2011). In vitro Selection of DNA Aptamers to Glioblastoma Multiforme. ACS Chem Neurosci 2: 175-181
9. Bruno, JG and Kiel, JL (1999). In vitro selection of DNA aptamers to anthrax spores with electrochemiluminescence detection. Biosens Bioelectron 14: 457-464 (Pubitemid 29333570)
10. Kirby, R, Cho, EJ, Gehrke, B, Bayer, T, Park, YS, Neikirk, DP et al. (2004). Aptamer-based sensor arrays for the detection and quantitation of proteins. Anal Chem 76: 4066-4075 (Pubitemid 38943679)
11. Shangguan, D, Li, Y, Tang, Z, Cao, ZC, Chen, HW, Mallikaratchy, P et al. (2006). Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA 103: 11838-11843 (Pubitemid 44215773)
12. Tang, Z, Parekh, P, Turner, P, Moyer, RW and Tan, W (2009). Generating aptamers for recognition of virus-infected cells. Clin Chem 55: 813-822
13. Que-Gewirth, NS and Sullenger, BA (2007). Gene therapy progress and prospects: RNA aptamers. Gene Ther 14: 283-291 (Pubitemid 46231922)
14. Sundaram, P, Kurniawan, H, Byrne, ME and Wower, J (2013). Therapeutic RNA aptamers in clinical trials. Eur J Pharm Sci 48: 259-271
15. Ireson, CR and Kelland, LR (2006). Discovery and development of anticancer aptamers. Mol Cancer Ther 5: 2957-2962 (Pubitemid 46092036)
16. Schmidt, KS, Borkowski, S, Kurreck, J, Stephens, AW, Bald, R, Hecht, M et al. (2004). Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res 32: 5757-5765 (Pubitemid 39619159)
17. Song, KM, Lee, S and Ban, C (2012). Aptamers and their biological applications. Sensors (Basel) 12: 612-631
18. Soutschek, J, Akinc, A, Bramlage, B, Charisse, K, Constien, R, Donoghue, M et al. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432: 173-178 (Pubitemid 39545841)
19. Keefe, AD and Cload, ST (2008). SELEX with modified nucleotides. Curr Opin Chem Biol 12: 448-456
20. Wu, SY, Yang, X, Gharpure, KM, Hatakeyama, H, Egli, M, McGuire, MH et al. (2014). 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun 5: 3459
21. Förster, C, Zydek, M, Rothkegel, M, Wu, Z, Gallin, C, Geßner, R et al. (2012). Properties of an LNA-modified ricin RNA aptamer. Biochem Biophys Res Commun 419: 60-65
22. Eulberg, D and Klussmann, S (2003). Spiegelmers: biostable aptamers. Chembiochem 4: 979-983 (Pubitemid 37267585)
23. Parekh, P, Kamble, S, Zhao, N, Zeng, Z, Portier, BP and Zu, Y (2013). Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer. Biomaterials 34: 8909-8917
24. Mallikaratchy, P, Stahelin, RV, Cao, Z, Cho, W and Tan, W (2006). Selection of DNA ligands for protein kinase C-delta. Chem Commun (Camb) 30: 3229-3231 (Pubitemid 44126575)
25. Martin, JA, Parekh, P, Kim, Y, Morey, TE, Sefah, K, Gravenstein, N et al. (2013). Selection of an aptamer antidote to the anticoagulant drug bivalirudin. PLoS ONE 8: e57341
26. Gopinath, SC (2007). Methods developed for SELEX. Anal Bioanal Chem 387: 171-182 (Pubitemid 44956270)
27. Yang, X, Bassett, SE, Li, X, Luxon, BA, Herzog, NK, Shope, RE et al. (2002). Construction and selection of bead-bound combinatorial oligonucleoside phosphorothioate and phosphorodithioate aptamer libraries designed for rapid PCR-based sequencing. Nucleic Acids Res 30: e132
28. Yang, X, Li, X, Prow, TW, Reece, LM, Bassett, SE, Luxon, BA et al. (2003). Immunofluorescence assay and flow-cytometry selection of bead-bound aptamers. Nucleic Acids Res 31: e54
29. Gold, L, Ayers, D, Bertino, J, Bock, C, Bock, A, Brody, EN et al. (2010). Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS ONE 5: e15004
30. Kraemer, S, Vaught, JD, Bock, C, Gold, L, Katilius, E, Keeney, TR et al. (2011). From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmerbased, streamlined multiplex proteomic assay. PLoS ONE 6: e26332
31. He, W, Elizondo-Riojas, MA, Li, X, Lokesh, GL, Somasunderam, A, Thiviyanathan, V et al. (2012). X-aptamers: a bead-based selection method for random incorporation of druglike moieties onto next-generation aptamers for enhanced binding. Biochemistry 51: 8321-8323
32. Ray, P, Sullenger, BA and White, RR (2013). Further characterization of the target of a potential aptamer biomarker for pancreatic cancer: cyclophilin B and its posttranslational modifications. Nucleic Acid Ther 23: 435-442
33. Sefah, K, Shangguan, D, Xiong, X, O'Donoghue, MB and Tan, W (2010). Development of DNA aptamers using Cell-SELEX. Nat Protoc 5: 1169-1185
34. Shigdar, S, Qiao, L, Zhou, SF, Xiang, D, Wang, T, Li, Y et al. (2013). RNA aptamers targeting cancer stem cell marker CD133. Cancer Lett 330: 84-95
35. Cerchia, L, Ducongé, F, Pestourie, C, Boulay, J, Aissouni, Y, Gombert, K et al. (2005). Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol 3: e123
36. Hicke, BJ, Marion, C, Chang, YF, Gould, T, Lynott, CK, Parma, D et al. (2001). Tenascin-C aptamers are generated using tumor cells and purified protein. J Biol Chem 276: 48644-48654
37. Wilner, SE, Wengerter, B, Maier, K, de Lourdes Borba Magalhães, M, Del Amo, DS, Pai, S et al. (2012). An RNA alternative to human transferrin: a new tool for targeting human cells. Mol Ther Nucleic Acids 1: e21
38. Yan, A and Levy, M (2014). Cell internalization SELEX: in vitro selection for molecules that internalize into cells. Methods Mol Biol 1103: 241-265
39. Gourronc, FA, Rockey, WM, Thiel, WH, Giangrande, PH and Klingelhutz, AJ (2013). Identification of RNA aptamers that internalize into HPV-16 E6/E7 transformed tonsillar epithelial cells. Virology 446: 325-333
40. Zhou, J, Bobbin, ML, Burnett, JC and Rossi, JJ (2012). Current progress of RNA aptamerbased therapeutics. Front Genet 3: 234
41. Thiel, WH, Bair, T, Peek, AS, Liu, X, Dassie, J, Stockdale, KR et al. (2012). Rapid identification of cell-specific, internalizing RNA aptamers with bioinformatics analyses of a cell-based aptamer selection. PLoS ONE 7: e43836
42. Camorani, S, Esposito, CL, Rienzo, A, Catuogno, S, Iaboni, M, Condorelli, G et al. (2014). Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRß aptamer. Mol Ther 22: 828-841
43. Thiel, KW, Hernandez, LI, Dassie, JP, Thiel, WH, Liu, X, Stockdale, KR et al. (2012). Delivery of chemo-sensitizing siRNAs to HER2+-breast cancer cells using RNA aptamers. Nucleic Acids Res 40: 6319-6337
44. Mayer, G, Ahmed, MS, Dolf, A, Endl, E, Knolle, PA and Famulok, M (2010). Fluorescenceactivated cell sorting for aptamer SELEX with cell mixtures. Nat Protoc 5: 1993-2004
45. Avci-Adali, M, Metzger, M, Perle, N, Ziemer, G and Wendel, HP (2010). Pitfalls of cellsystematic evolution of ligands by exponential enrichment (SELEX): existing dead cells during in vitro selection anticipate the enrichment of specific aptamers. Oligonucleotides 20: 317-323
46. Dua, P, Kang, HS, Hong, SM, Tsao, MS, Kim, S and Lee, DK (2013). Alkaline phosphatase ALPPL-2 is a novel pancreatic carcinoma-associated protein. Cancer Res 73: 1934-1945
47. Tang, Z, Shangguan, D, Wang, K, Shi, H, Sefah, K, Mallikratchy, P et al. (2007). Selection of aptamers for molecular recognition and characterization of cancer cells. Anal Chem 79: 4900-4907 (Pubitemid 47051443)
48. Mallikaratchy, P, Tang, Z, Kwame, S, Meng, L, Shangguan, D and Tan, W (2007). Aptamer directly evolved from live cells recognizes membrane bound immunoglobin heavy mu chain in Burkitt's lymphoma cells. Mol Cell Proteomics 6: 2230-2238
49. Shangguan, D, Cao, Z, Meng, L, Mallikaratchy, P, Sefah, K, Wang, H et al. (2008). Cellspecific aptamer probes for membrane protein elucidation in cancer cells. J Proteome Res 7: 2133-2139
50. Josic, D, Clifton, JG, Kovac, S and Hixson, DC (2008). Membrane proteins as diagnostic biomarkers and targets for new therapies. Curr Opin Mol Ther 10: 116-123 (Pubitemid 351498873)
51. Yildirim, MA, Goh, KI, Cusick, ME, Barabási, AL and Vidal, M (2007). Drug-target network. Nat Biotechnol 25: 1119-1126 (Pubitemid 47538114)
52. Esposito, CL, Passaro, D, Longobardo, I, Condorelli, G, Marotta, P, Affuso, A et al. (2011). A neutralizing RNA aptamer against EGFR causes selective apoptotic cell death. PLoS ONE 6: e24071
53. Chen, HW, Medley, CD, Sefah, K, Shangguan, D, Tang, Z, Meng, L et al. (2008). Molecular recognition of small-cell lung cancer cells using aptamers. ChemMedChem 3: 991-1001
54. Zhao, Z, Xu, L, Shi, X, Tan, W, Fang, X and Shangguan, D (2009). Recognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells. Analyst 134: 1808-1814
55. Wang, FB, Rong, Y, Fang, M, Yuan, JP, Peng, CW, Liu, SP et al. (2013). Recognition and capture of metastatic hepatocellular carcinoma cells using aptamer-conjugated quantum dots and magnetic particles. Biomaterials 34: 3816-3827
56. Kim, MY and Jeong, S (2011). In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells. Nucleic Acid Ther 21: 173-178
57. Zhang, K, Sefah, K, Tang, L, Zhao, Z, Zhu, G, Ye, M et al. (2012). A novel aptamer developed for breast cancer cell internalization. ChemMedChem 7: 79-84
58. Van Simaeys, D, López-Colón, D, Sefah, K, Sutphen, R, Jimenez, E and Tan, W (2010). Study of the molecular recognition of aptamers selected through ovarian cancer cell- SELEX. PLoS ONE 5: e13770
59. Cerchia, L, Esposito, CL, Jacobs, AH, Tavitian, B and de Franciscis, V (2009). Differential SELEX in human glioma cell lines. PLoS ONE 4: e7971
60. Kang, D, Wang, J, Zhang, W, Song, Y, Li, X, Zou, Y et al. (2012). Selection of DNA aptamers against glioblastoma cells with high affinity and specificity. PLoS ONE 7: e42731
61. Sefah, K, Meng, L, Lopez-Colon, D, Jimenez, E, Liu, C and Tan, W (2010). DNA aptamers as molecular probes for colorectal cancer study. PLoS ONE 5: e14269
62. Sefah, K, Bae, KM, Phillips, JA, Siemann, DW, Su, Z, McClellan, S et al. (2013). Cellbased selection provides novel molecular probes for cancer stem cells. Int J Cancer 132: 2578-2588
63. Subramanian, N, Raghunathan, V, Kanwar, JR, Kanwar, RK, Elchuri, SV, Khetan, V et al. (2012). Target-specific delivery of doxorubicin to retinoblastoma using epithelial cell adhesion molecule aptamer. Mol Vis 18: 2783-2795
64. Liu, Z, Duan, JH, Song, YM, Ma, J, Wang, FD, Lu, X et al. (2012). Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. J Transl Med 10: 148
65. Hu, Y, Duan, J, Zhan, Q, Wang, F, Lu, X and Yang, X-D (2012). Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro. PloS One 7: e31970
66. Bagalkot, V, Farokhzad, OC, Langer, R and Jon, S (2006). An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl 45: 8149-8152 (Pubitemid 44974149)
67. Huang, YF, Shangguan, D, Liu, H, Phillips, JA, Zhang, X, Chen, Y et al. (2009). Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem 10: 862-868
68. McGinely, NL, Plumb, JA and Wheate, NJ (2013). DNA-based aptamer fails as a simultaneous cancer targeting agent and drug delivery vehicle for a phenanthroline-based platinum(II) complex. J Inorg Biochem 128: 124-130
69. Boyacioglu, O, Stuart, CH, Kulik, G and Gmeiner, WH (2013). Dimeric DNA Aptamer Complexes for High-capacity-targeted Drug Delivery Using pH-sensitive Covalent Linkages. Mol Ther Nucleic Acids 2: e107
70. Tan, L, Neoh, KG, Kang, ET, Choe, WS and Su, X (2011). PEGylated anti-MUC1 aptamerdoxorubicin complex for targeted drug delivery to MCF7 breast cancer cells. Macromol Biosci 11: 1331-1335
71. Taghdisi, SM, Danesh, NM, Sarreshtehdar Emrani, A, Tabrizian, K, Zandkarimi, M, Ramezani, M et al. (2013). Targeted delivery of Epirubicin to cancer cells by PEGylated A10 aptamer. J Drug Target 21: 739-744
72. Zhu, G, Zheng, J, Song, E, Donovan, M, Zhang, K, Liu, C et al. (2013). Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics. Proc Natl Acad Sci USA 110: 7998-8003
73. Tan, L, Gee Neoh, K, Kang, ET, Choe, WS and Su, X (2012). Designer tridentate mucin 1 aptamer for targeted drug delivery. J Pharm Sci 101: 1672-1677
74. Zhang, Z, Ali, MM, Eckert, MA, Kang, DK, Chen, YY, Sender, LS et al. (2013). A polyvalent aptamer system for targeted drug delivery. Biomaterials 34: 9728-9735
75. Ray, P, Cheek, MA, Sharaf, ML, Li, N, Ellington, AD, Sullenger, BA et al. (2012). Aptamermediated delivery of chemotherapy to pancreatic cancer cells. Nucleic Acid Ther 22: 295-305
76. Ferreira, CS, Cheung, MC, Missailidis, S, Bisland, S and Gariépy, J (2009). Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res 37: 866-876
77. Shieh, YA, Yang, SJ, Wei, MF and Shieh, MJ (2010). Aptamer-based tumor-targeted drug delivery for photodynamic therapy. ACS Nano 4: 1433-1442
78. Liu, Q, Xu, L, Zhang, X, Li, N, Zheng, J, Guan, M et al. (2013). Enhanced photodynamic efficiency of an aptamer-guided fullerene photosensitizer toward tumor cells. Chem Asian J 8: 2370-2376
79. Zhu, G, Meng, L, Ye, M, Yang, L, Sefah, K, O'Donoghue, MB et al. (2012). Self-assembled aptamer-based drug carriers for bispecific cytotoxicity to cancer cells. Chem Asian J 7: 1630-1636
80. Min, K, Jo, H, Song, K, Cho, M, Chun, YS, Jon, S et al. (2011). Dual-aptamer-based delivery vehicle of doxorubicin to both PSMA (+) and PSMA (-) prostate cancers. Biomaterials 32: 2124-2132
81. Farokhzad, OC, Jon, S, Khademhosseini, A, Tran, TN, Lavan, DA and Langer, R (2004). Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 64: 7668-7672 (Pubitemid 39446893)
82. Farokhzad, OC, Cheng, J, Teply, BA, Sherifi, I, Jon, S, Kantoff, PW et al. (2006). Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 103: 6315-6320
83. Yu, C, Hu, Y, Duan, J, Yuan, W, Wang, C, Xu, H et al. Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PloS One 6: e24077
84. Aravind, A, Jeyamohan, P, Nair, R, Veeranarayanan, S, Nagaoka, Y, Yoshida, Y et al. (2012). AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery. Biotechnol Bioeng 109: 2920-2931
85. Guo, J, Gao, X, Su, L, Xia, H, Gu, G, Pang, Z et al. (2011). Aptamer-functionalized PEGPLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials 32: 8010-8020
86. Xing, H, Tang, L, Yang, X, Hwang, K, Wang, W, Yin, Q et al. (2013). Selective Delivery of an Anticancer Drug with Aptamer-Functionalized Liposomes to Breast Cancer Cells in Vitro and in Vivo. J Mater Chem B Mater Biol Med 1: 5288-5297
87. Dhar, S, Gu, FX, Langer, R, Farokhzad, OC and Lippard, SJ (2008). Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc Natl Acad Sci USA 105: 17356-17361
88. Dhar, S, Kolishetti, N, Lippard, SJ and Farokhzad, OC (2011). Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci USA 108: 1850-1855
89. Wu, Y, Sefah, K, Liu, H, Wang, R and Tan, W (2010). DNA aptamer-micelle as an efficient detection/delivery vehicle toward cancer cells. Proc Natl Acad Sci USA 107: 5-10
90. Xu, W, Siddiqui, IA, Nihal, M, Pilla, S, Rosenthal, K, Mukhtar, H et al. (2013). Aptamerconjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer. Biomaterials 34: 5244-5253
91. Zhao, N, You, J, Zeng, Z, Li, C and Zu, Y (2013). An ultra pH-sensitive and aptamerequipped nanoscale drug-delivery system for selective killing of tumor cells. Small 9: 3477-3484
92. Wang, J, Sefah, K, Altman, MB, Chen, T, You, M, Zhao, Z et al. (2013). Aptamer-conjugated nanorods for targeted photothermal therapy of prostate cancer stem cells. Chem Asian J 8: 2417-2422
93. Wang, J, You, M, Zhu, G, Shukoor, MI, Chen, Z, Zhao, Z et al. (2013). Photosensitizer-gold nanorod composite for targeted multimodal therapy. Small 9: 3678-3684
94. Jalalian, SH, Taghdisi, SM, Shahidi Hamedani, N, Kalat, SA, Lavaee, P, Zandkarimi, M et al. (2013). Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo. Eur J Pharm Sci 50: 191-197
95. Tong, GJ, Hsiao, SC, Carrico, ZM and Francis, MB (2009). Viral capsid DNA aptamer conjugates as multivalent cell-targeting vehicles. J Am Chem Soc 131: 11174-11178
96. Cohen, BA and Bergkvist, M (2013). Targeted in vitro photodynamic therapy via aptamerlabeled, porphyrin-loaded virus capsids. J Photochem Photobiol B, Biol 121: 67-74
97. Liu, J, Liu, H, Kang, H, Donovan, M, Zhu, Z and Tan, W (2012). Aptamer-incorporated hydrogels for visual detection, controlled drug release, and targeted cancer therapy. Anal Bioanal Chem 402: 187-194
98. Yang, L, Zhang, X, Ye, M, Jiang, J, Yang, R, Fu, T et al. (2011). Aptamer-conjugated nanomaterials and their applications. Adv Drug Deliv Rev 63: 1361-1370
99. Ray, P, Viles, KD, Soule, EE and Woodruff, RS (2013). Application of aptamers for targeted therapeutics. Arch Immunol Ther Exp (Warsz) 61: 255-271
100. McNamara, JO 2nd, Andrechek, ER, Wang, Y, Viles, KD, Rempel, RE, Gilboa, E et al. (2006). Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24: 1005-1015 (Pubitemid 44215395)
101. Neff, CP, Zhou, J, Remling, L, Kuruvilla, J, Zhang, J, Li, H et al. (2011). An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci Transl Med 3: 66-6.
102. Zhou, J, Swiderski, P, Li, H, Zhang, J, Neff, CP, Akkina, R et al. (2009). Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res 37: 3094-3109
103. Zhou, J, Li, H, Li, S, Zaia, J and Rossi, JJ (2008). Novel dual inhibitory function aptamersiRNA delivery system for HIV-1 therapy. Mol Ther 16: 1481-1489
104. Zhou, J, Tiemann, K, Chomchan, P, Alluin, J, Swiderski, P, Burnett, J et al. (2013). Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells. Nucleic Acids Res 41: 4266-4283
105. Wullner, U, Neef, I, Eller, A, Kleines, M, Tur, MK and Barth, S (2008). Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. Curr Cancer Drug Targets 8: 554-565
106. Chu, TC, Twu, KY, Ellington, AD and Levy, M (2006). Aptamer mediated siRNA delivery. Nucleic Acids Res 34: e73
107. Zhao, N, Bagaria, HG, Wong, MS and Zu, Y (2011). A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma. J Nanobiotechnology 9: 2
108. Bagalkot, V and Gao, X (2011). siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing. ACS Nano 5: 8131-8139
109. Dai, F, Zhang, Y, Zhu, X, Shan, N and Chen, Y (2012). Anticancer role of MUC1 aptamermiR- 29b chimera in epithelial ovarian carcinoma cells through regulation of PTEN methylation. Target Oncol 7: 217-225
110. Dai, F, Zhang, Y, Zhu, X, Shan, N and Chen, Y (2013). The anti-chemoresistant effect and mechanism of MUC1 aptamer-miR-29b chimera in ovarian cancer. Gynecol Oncol 131: 451-459
111. Bruno, JG, Carrillo, MP and Crowell, R (2009). Preliminary development of DNA aptamer- Fc conjugate opsonins. J Biomed Mater Res A 90: 1152-1161
112. Stecker, JR, Savage, AA, Bruno, JG, García, DM and Koke, JR (2012). Dynamics and visualization of MCF7 adenocarcinoma cell death by aptamer-C1q-mediated membrane attack. Nucleic Acid Ther 22: 275-282
113. Boltz, A, Piater, B, Toleikis, L, Guenther, R, Kolmar, H and Hock, B (2011). Bi-specific aptamers mediating tumor cell lysis. J Biol Chem 286: 21896-21905
114. Xiong, X, Liu, H, Zhao, Z, Altman, MB, Lopez-Colon, D, Yang, CJ et al. (2013). DNA aptamer-mediated cell targeting. Angew Chem Int Ed Engl 52: 1472-1476
115. Mahlknecht, G, Maron, R, Mancini, M, Schechter, B, Sela, M and Yarden, Y (2013). Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth. Proc Natl Acad Sci USA 110: 8170-8175
116. Cho, M, Soo Oh, S, Nie, J, Stewart, R, Eisenstein, M, Chambers, J et al. (2013). Quantitative selection and parallel characterization of aptamers. Proc Natl Acad Sci USA 110: 18460-18465
117. Li, S, Xu, H, Ding, H, Huang, Y, Cao, X, Yang, G et al. (2009). Identification of an aptamer targeting hnRNP A1 by tissue slide-based SELEX. J Pathol 218: 327-336
118. Mi, J, Liu, Y, Rabbani, ZN, Yang, Z, Urban, JH, Sullenger, BA et al. (2010). In vivo selection of tumor-targeting RNA motifs. Nat Chem Biol 6: 22-24
119. Liu, J, Liu, H, Sefah, K, Liu, B, Pu, Y, Van Simaeys, D et al. (2012). Selection of aptamers specific for adipose tissue. PloS One 7: e37789
120. Cheng, C, Chen, YH, Lennox, KA, Behlke, MA and Davidson, BL (2013). In vivo SELEX for Identification of Brain-penetrating Aptamers. Mol Ther Nucleic Acids 2: e67
121. Saifer, MG, Williams, LD, Sobczyk, MA, Michaels, SJ and Sherman, MR (2014). Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins. Mol Immunol 57: 236-246
122. Kim, E, Jung, Y, Choi, H, Yang, J, Suh, JS, Huh, YM et al. (2010). Prostate cancer cell death produced by the co-delivery of Bcl-xL shRNA and doxorubicin using an aptamerconjugated polyplex. Biomaterials 31: 4592-4599
123. Cerchia, L, Esposito, CL, Camorani, S, Rienzo, A, Stasio, L, Insabato, L et al. (2012). Targeting Axl with an high-affinity inhibitory aptamer. Mol Ther 20: 2291-2303
124. Lee, YJ, Han, SR, Kim, NY, Lee, SH, Jeong, JS and Lee, SW (2012). An RNA aptamer that binds carcinoembryonic antigen inhibits hepatic metastasis of colon cancer cells in mice. Gastroenterology 143: 155-65.e8
125. Pastor, F, Soldevilla, MM, Villanueva, H, Kolonias, D, Inoges, S, de Cerio, AL et al. (2013). CD28 aptamers as powerful immune response modulators. Mol Ther Nucleic Acids 2: e98
126. Mori, T, Oguro, A, Ohtsu, T and Nakamura, Y (2004). RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family. Nucleic Acids Res 32: 6120-6128 (Pubitemid 40074006)
127. Ababneh, N, Alshaer, W, Allozi, O, Mahafzah, A, El-Khateeb, M, Hillaireau, H et al. (2013). In vitro selection of modified RNA aptamers against CD44 cancer stem cell marker. Nucleic Acid Ther 23: 401-407
128. Somasunderam, A, Thiviyanathan, V, Tanaka, T, Li, X, Neerathilingam, M, Lokesh, GL et al. (2010). Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of human CD44. Biochemistry 49: 9106-9112
129. Roth, F, De La Fuente, AC, Vella, JL, Zoso, A, Inverardi, L and Serafini, P (2012). Aptamermediated blockade of IL4Ra triggers apoptosis of MDSCs and limits tumor progression. Cancer Res 72: 1373-1383
130. Li, N, Nguyen, HH, Byrom, M and Ellington, AD (2011). Inhibition of cell proliferation by an anti-EGFR aptamer. PLoS ONE 6: e20299
131. Dastjerdi, K, Tabar, GH, Dehghani, H and Haghparast, A (2011). Generation of an enriched pool of DNA aptamers for an HER2-overexpressing cell line selected by Cell SELEX. Biotechnol Appl Biochem 58: 226-230
132. Chen, CH, Chernis, GA, Hoang, VQ and Landgraf, R (2003). Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc Natl Acad Sci USA 100: 9226-9231 (Pubitemid 37033911)
133. Mann, AP, Somasunderam, A, Nieves-Alicea, R, Li, X, Hu, A, Sood, AK et al. (2010). Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting. PLoS ONE 5: e13050
134. Mann, AP, Tanaka, T, Somasunderam, A, Liu, X, Gorenstein, DG and Ferrari, M (2011). E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow. Adv Mater Weinheim 23: H278-H282
135. Mann, AP, Bhavane, RC, Somasunderam, A, Liz Montalvo-Ortiz, B, Ghaghada, KB, Volk, D et al. (2011). Thioaptamer conjugated liposomes for tumor vasculature targeting. Oncotarget 2: 298-304
136. Song, Y, Zhu, Z, An, Y, Zhang, W, Zhang, H, Liu, D et al. (2013). Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture. Anal Chem 85: 4141-4149
137. Shigdar, S, Lin, J, Yu, Y, Pastuovic, M, Wei, M and Duan, W (2011). RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci 102: 991-998
138. Waybrant, B, Pearce, TR, Wang, P, Sreevatsan, S and Kokkoli, E (2012). Development and characterization of an aptamer binding ligand of fractalkine using domain targeted SELEX. Chem Commun (Camb) 48: 10043-10045
139. Toscano-Garibay, JD, Benítez-Hess, ML and Alvarez-Salas, LM (2011). Isolation and characterization of an RNA aptamer for the HPV-16 E7 oncoprotein. Arch Med Res 42: 88-96
140. Mi, J, Zhang, X, Giangrande, PH, McNamara, JO 2nd, Nimjee, SM, Sarraf-Yazdi, S et al. (2005). Targeted inhibition of alphavbeta3 integrin with an RNA aptamer impairs endothelial cell growth and survival. Biochem Biophys Res Commun 338: 956-963 (Pubitemid 41597735)
141. Da Rocha Gomes, S, Miguel, J, Azéma, L, Eimer, S, Ries, C, Dausse, E et al. (2012). (99m)Tc-MAG3-aptamer for imaging human tumors associated with high level of matrix metalloprotease-9. Bioconjug Chem 23: 2192-2200
142. Ferreira, CS, Matthews, CS and Missailidis, S (2006). DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumour Biol 27: 289-301 (Pubitemid 44646223)
143. Lupold, SE, Hicke, BJ, Lin, Y and Coffey, DS (2002). Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostatespecific membrane antigen. Cancer Res 62: 4029-4033. (Pubitemid 34791070)